

Provider Issue



CONTRA COSTA HEALTH PLAN 595 Center Avenue Suite 100 Martinez, CA 94553 925.313.6000

Date: December 2022

Contra Costa Health Plan Pharmacy and Therapeutics Committee (P&T)

The CCHP P&T committee met on 12/2/2022. Updates from the meeting are outlined below:

Changes to the PDL will be effective by mid-January 2023

Updates/Announcements:

1. Schedule for Medi-Cal Rx Reinstatement of Prior Authorization Requirements:

Medi-Cal Rx Reinstatement

Reinstatement Phase II - Phase IV



Key Dates

- January 20, 2023: Phase II, Wave 1 begins for new starts only.
- February 24, 2023: Phase II, Wave 2 begins.
- March 24, 2023 June 23, 2023: Series of Transition Lifts.

For additional details including the specific medications in each phase, please go to the DHCS Medi-Cal Rx website at https://www.medi-calrx.dhcs.ca.gov/home/education/ or contact CCHP Pharmacy Department for more details.

2. Medi-Cal Rx Formulary Changes:

Medi-Cal Rx has been updating their Contract Drug List (CDL) on a monthly basis.

These updates can be found on the DHCS Medi-Cal Rx website at https://medi-calrx.dhcs.ca.gov/provider/pharmacy-news or contact the CCHP Pharmacy Department for additional details.

Quick reference table for all changes to the Preferred Drug List (PDL) and/or Prior Authorization (PA) criteria (for full details of each change, please see individual drugs listed below this table or contact	
the CCHP Pharmacy Department):	
<u>Changes Made</u>	<u>Drug Name</u>
Created new PA criteria:	Kerendia (finerenone)
	Mounjaro (tirzepatide)
Modified PA criteria:	Anti-obesity medications
	Botox (onabotulinumtoxinA)
	Testosterone products
	·
ADDED to the CCHP formulary:	Tecfidera (dimethyl fumarate)
	Breo Ellipta (fluticasone/vilanterol)
	Flovent HFA (fluticasone propionate)
	, , , ,
Removed from CCHP formulary:	Advair HFA (fluticasone/salmeterol)

- New Pharmacy Criteria for Kerendia (finerenone): Member must have a diagnosis of chronic kidney disease associated with type 2 diabetes, currently taking an ACE inhibitor or ARB and documented trial and failure of an SGLT2 inhibitor.
- New Pharmacy Criteria for Mounjaro (tizepatide): Member must have a diagnosis of type 2 diabetes, documented trial and failure of metformin and documented trial and failure of one of the following preferred products: Victoza, Ozempic, Rybelsus or Trulicity.
- Modification of pharmacy criteria for anti-obesity medications: Previously, this class of
 medications had a requirement to try and fail orlistat as step therapy. This step therapy
 requirement has now been dropped.
- Modification of medical criteria for Botox (onabotulinumtoxinA): added nortriptyline and duloxetine as potential medications to qualify for previous trial and failure requirements. Also added criteria for chronic sialorrhea (member has had sialorrhea for at least 3 months and has tried and failed an anticholinergic medication).
- Modification of pharmacy criteria for testosterone products: moved Androgel 1.62% pump and Axiron 30 mg/1.5 mL pump to 2nd line preferred status and moved Androgel 1% packets to 3rd line preferred status.

There are numerous ways to view the CCHP Preferred Drug List:

CCHP updates the Preferred Drug List (PDL) after each quarterly Pharmacy & Therapeutics Committee meeting. CCHP invites and encourages practitioners to access each update through the following means:

e epocrates

- An interactive searchable formulary is available within Epic (contact the Epic team with any
 questions related to functionality).
- A printable copy of the CCHP PDL can be found here: http://cchealth.org/healthplan/pdf/pdl.pdf
- A searchable copy of the CCHP PDL can be found here: https://cchealth.org/healthplan/formulary.php
- EPOCRATES free mobile & online formulary resource
 - CCHP providers may add the CCHP formulary to their mobile devices using the following steps:
 - Open the Epocrates application on your mobile device.

- Click on the "formulary" button on the home screen.
- Click "add new formulary" button on the bottom of the screen.
- Use the search box to locate "Contra Costa Health Plan" Medi-Cal or Commercial formulary. Click on each formulary that you would like to add, and then click the "add formulary" button.

Providers may request a copy of CCHP pharmacy management procedures or specific drug PA criteria by contacting the pharmacy unit directly at 925-957-7260 x1, or via the email listed below:

P&T updates and DUR educational bulletins can be viewed online at http://cchealth.org/healthplan/provider-pharmacy-therapeutics.php

Questions and comments may be directed to CCHP Pharmacy by emailing joseph.cardinalli@cchealth.org